Remove Cerebrovascular Disease Remove Peripheral Arterial Disease Remove Quality of Life
article thumbnail

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan area of Brandenburg, Germany

Frontiers in Cardiovascular Medicine

Patients underwent a comprehensive angiological screening, which included blood serum analysis, assessment of medical and family history, cardiovascular risk, and disease status, and evaluation of lifestyle and quality of life. 3.95, p  = 0.003). 3.95, p  = 0.003). vs. 45.8%; 17.6% vs. 13.9%, p  = 0.001).

article thumbnail

CorVascular’s VasoGuard Earns FDA 510(k) Clearance

DAIC

mtaschetta-millane Mon, 07/29/2024 - 09:16 July 29, 2024 — CorVascular , a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) testing devices, today announced the U.S. Food and Drug Administration (FDA) has cleared its VasoGuard V-Series as Class II medical devices.